title: Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients.
abstract: In vivo administration of escalation doses of recombinant alpha-interferon (IFN-alpha) during a phase I trial in malignant melanoma patients caused dose-dependent increases in the mRNA accumulation, synthesis, steady state cellular content, and plasma membrane expression of class I major histocompatibility complex molecules in peripheral blood mononuclear cells. In addition, circulating levels of class I molecules were also enhanced. These findings show that (a) antigenic enhancement by biomodifiers may occur in vivo, in humans and (b) the mechanism of class I major histocompatibility complex enhancement by IFN-alpha is similar in vitro and in vivo. Furthermore, because peripheral blood mononuclear cells of different melanoma patients display different susceptibility to IFN-alpha, the entity of their antigenic modulation may represent a useful parameter to evaluate the efficacy of different therapeutic regimens and/or assess the individual susceptibility to the molecular changes induced by IFN-alpha.
authors.affiliation: Immunology Department, Regina Elena Institute, Rome, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Giacomini
authors.forename: R
authors.initials: R
authors.lastname: Fraioli
authors.forename: A M
authors.initials: AM
authors.lastname: Calabrò
authors.forename: F
authors.initials: F
authors.lastname: Di Filippo
authors.forename: P G
authors.initials: PG
authors.lastname: Natali
mesh_terms: D000911:Antibodies, Monoclonal; D002462:Cell Membrane / Q000276:immunology; D002469:Cell Separation; D002499:Centrifugation, Density Gradient; D005805:Genes, MHC Class I / Q000187:drug effects*; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007700:Kinetics; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008545:Melanoma / Q000097:blood / Q000276:immunology* / Q000628:therapy; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D011994:Recombinant Proteins; D014158:Transcription, Genetic / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D015395:Histocompatibility Antigens Class I; D007370:Interferon Type I; D012333:RNA, Messenger; D011994:Recombinant Proteins